Abstract: A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed.

Abstract: A device for packaging, conserving, and extemporaneously preparing a plurality of active principles, including a reservoir having a compartment for containing a volume of liquid, the reservoir including a neck defining a dispenser opening; a head that is movable relative to the reservoir between a first distal position for conservation and a second proximate position for preparation; a leaktight closure mechanism; and a rupture mechanism for rupturing the closure mechanism. The closure mechanism is formed by a blister that contains at least two active principles and has at least two compartments, each compartment containing an active principle. The blister is fastened on the neck of the reservoir so as to close it, such that after opening the blister by the rupture mechanism, the active principles enter into contact with the liquid and dissolve therein.

Abstract: A device for administering an active principle via the oral mucous membrane, having an ampule (1) containing liquid, the ampule including an opening defining a peripheral axial edge (11) closed by a film (10); a syringe barrel (2) with a dispenser orifice; a piston (3) in the syringe barrel (2); a piston rod (4); and a connector (20) formed integrally with or fastened to the syringe barrel (2) and adapted to be connected in leaktight manner to the ampule. The connector includes a perforator (23) for perforating the film and connecting the inside of the ampule with the syringe barrel, the perforator forming the dispenser orifice while the active principle is dispensed. The connector includes an outer protective skirt (21) for creating a gum/cheek cavity while the liquid is deposited and includes an annular reception space (24) for receiving the peripheral axial edge of the ampule.

Abstract: A galenical form for the buccal transmucous administration of at least one active ingredient of the triptan family, includes at least: the active ingredient in basic form and in salt form, and a hydro-alcoholic solution that titrates at least 15 degrees of alcohol, whereby the active ingredient is present in a stable and complete state of dissolution in the hydro-alcoholic solution so as to allow a fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for the production of this galenical formulation as well as its use are described.

Abstract: A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an aqueous alcohol solution titrating at least 35° alcohol by weight, the active principle being present in a state of stable and complete dissolution in the aqueous alcohol solution. Also, a method of preparing this formulation and its use for treating spastic crises.

Abstract: A device for packaging, conserving, and extemporaneously preparing a plurality of active principles, including a reservoir having a compartment for containing a volume of liquid, the reservoir including a neck defining a dispenser opening; a head that is movable relative to the reservoir between a first distal position for conservation and a second proximate position for preparation; a leaktight closure mechanism; and a rupture mechanism for rupturing the closure mechanism. The closure mechanism is formed by a blister that contains at least two active principles and has at least two compartments, each compartment containing an active principle. The blister is fastened on the neck of the reservoir so as to close it, such that after opening the blister by the rupture mechanism, the active principles enter into contact with the liquid and dissolve therein.

Abstract: A device for packaging, conserving, and extemporaneously preparing a plurality of active principles, including a reservoir having a compartment for containing a volume of liquid, the reservoir including a neck defining a dispenser opening; a head that is movable relative to the reservoir between a first distal position for conservation and a second proximate position for preparation; a leaktight closure mechanism; and a rupture mechanism for rupturing the closure mechanism. The closure mechanism is formed by a blister that contains at least two active principles and has at least two compartments, each compartment containing an active principle. The blister is fastened on the neck of the reservoir so as to close it, such that after opening the blister by the rupture mechanism, the active principles enter into contact with the liquid and dissolve therein.

Abstract: A dosage form for oral administration, via the mucous membranes, of an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder, the active principle being lipophilic or amphiphilic and being in a dissolved state that is stable and complete in a hydro-alcoholic solution having 35% to 70% by weight of ethanol and 30% to 65% by weight of water, generating nanostructures of the active principle under consideration within the hydro-alcoholic solution, thereby enabling the active principle to cross the blood-brain barrier, the active principle being in base and/or salt form and belonging to the chemical families of sleep inducers or modulators of lipophilic or amphiphilic type and of molecular weight that is less than 1000 Da, the active principle being selected from the families of Imidazopyridines, including Zolpidem, the family of Cyclopyrrolones, including Eszopiclone, the family of Pyrazolopyrimidines, including Zaleplon, the fa

Abstract: A method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. Also, disclosed is a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.

Abstract: A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva.

Abstract: The invention relates to a formulation for delivering by oral transmucosal administration at least one lipid-lowering active principle, preferably from the statin family, said formulation including said active principle in the base or salt form, an aqueous alcohol solution titrating at least 30° alcohol, and optionally a pH correcting agent and/or an antioxidant, said active principle being in a stable and completely dissolved state in the aqueous alcohol solution. The invention also relates to a method of preparing said formulation and to the use thereof, preferably in single-dose packaging, for treating and preventing hyperlipemia and/or cardiovascular conditions.

Abstract: The invention provides a device (10) for conserving and extemporaneously preparing at least one active principle prior to administration, the device comprising: a body (12) that is constituted by at least one compartment for containing at least one volume of pharmaceutical solvent (22) that is less than 5 mL; a head (14) constituted by at least one compartment for containing at least one active principle (24), in particular a very small dose, and, in its top portion, by at least one dose-taking chamber (32) provided with a filter (40), the head (14) being capable of taking up a first position P1 for conservation, in which said head (14) is in its distal position relative to the body (12), and a second position P2 for preparation, in which said head (14) is in its proximal position relative to the body (12); at least one wall (16) separating the body (12) and the head (14); and rupture means (18) for rupturing said wall (16) so that the active principle (24) enters into contact with the solvent (22) and dissol

Abstract: A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.

Abstract: A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.

Abstract: A device for packaging, conserving, and extemporaneously preparing a plurality of active principles, including a reservoir having a compartment for containing a volume of liquid, the reservoir including a neck defining a dispenser opening; a head that is movable relative to the reservoir between a first distal position for conservation and a second proximate position for preparation; a leaktight closure mechanism; and a rupture mechanism for rupturing the closure mechanism. The closure mechanism is formed by a blister that contains at least two active principles and has at least two compartments, each compartment containing an active principle. The blister is fastened on the neck of the reservoir so as to close it, such that after opening the blister by the rupture mechanism, the active principles enter into contact with the liquid and dissolve therein.

Abstract: The invention provides a packaging and administering device for administering a hydro-alcoholic solution by passing through a mucous membrane, the device comprising a deformable container for receiving at least one first fraction of the solution, a base that is secured to the container, and an administering tube that is secured to the base and that is suitable for receiving at least one second fraction of the solution, and that includes a cap. The tube includes a chamber for containing the at least one second solution and that is defined by two membranes, and the cap is movable in translation between two extreme positions and includes a needle for coming to pierce the two membranes in one of the extreme positions.

Abstract: The invention provides a container for preparing and/or administering a very small volume of active principles in liquid form, the container comprising a head (12) suitable for taking up a conservation, first position P1 in which said head (12) is in a distal position relative to the container, and an administration, second position P2 in which said head (12) is in a proximal position relative to the container, said head (12) including a cannula (14) with at least one flow channel (16), its length being adapted so that the free end of the flow channel (16) can enable delivery by sublingual and/or paragingival permeation, while the container is being held in the hand.

Abstract: The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. The invention also pertains to a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.

Abstract: A salivary substitute is produced from egg white so as to have chemical, rheological and physiological properties that are analogous to those of natural human saliva. A packaging containing the salivary substitute and uses of the salivary substitute are also disclosed.

Abstract: A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva.